Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-Part Prospective Study to Measure Impact of Prolaris® Testing Added to Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients to Measure Prediction of Progression/Recurrence in Men Treated at VAMC

NCT03152448 is registered in ClinicalTrials.gov with Myriad Genetic Laboratories, Inc. as lead sponsor.

NCT NCT03152448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03152448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-Part Prospective Study to Measure Impact of Prolaris® Testing Added to Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients to Measure Prediction of Progression/Recurrence in Men Treated at VAMC
Lead sponsor
Myriad Genetic Laboratories, Inc.
Phase
Observational
Overall status
Terminated
Start date
September 1, 2015
Completion date
March 21, 2022
Enrollment
1,511 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer